CompaniesImmune Control

Immune Control

defunct
About

Defunct Company

Areas of Focus

Categories

MergedBankrupt, Merged, Sold, Renamed or Otherwise Defunct
Clinical Trials (4)
View all

Total Trials

4

As Lead Sponsor

2

As Collaborator

2

Total Enrollment

85

By Phase

PHASE1: 1PHASE2: 2PHASE1/PHASE2: 1

By Status

COMPLETED: 2UNKNOWN: 1TERMINATED: 1
Clinical Trials Pipeline4 trials
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Phase 1/2
Phase 2/3
N/A
2005
2006
2007
2008
2009
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
2026
Today
NCT00335647
Hover over trial bars to see details

Recent Trials

NCT00821301Lead Sponsor
Study of Fluphenazine in Relapsed or Relapsed-and-Refractory Multiple Myeloma
PHASE1Unknown
30 participants
Started: Dec 31, 2008 · Completed: Oct 31, 2010
NCT00929578Collaborator
Fluphenazine Hydrochloride for Psoriasis
PHASE2Completed
15 participants
Started: Nov 30, 2008 · Completed: Jan 31, 2011
NCT00356200Collaborator
Fluphenazine Decanoate for Psoriasis
PHASE2Terminated
10 participants
Started: Jul 31, 2006 · Completed: Sep 30, 2008
NCT00335647Lead Sponsor
Fluphenazine in Treating Patients With Refractory Advanced Multiple Myeloma
PHASE1/PHASE2Completed
30 participants
Started: Jan 31, 2006
Related Companies
Arginetix To Become Corridor Pharmaceuticals
merged